Institute of Pharmaceutical Science, King's College London, London, UK; Centre for Therapeutic Innovation, University of Bath, Bath, UK.
Institute of Pharmaceutical Science, King's College London, London, UK.
Colloids Surf B Biointerfaces. 2022 Oct;218:112734. doi: 10.1016/j.colsurfb.2022.112734. Epub 2022 Jul 28.
Tumour-targeted near-infrared (NIR) optical imaging is an emerging tool for the detection of malignant tissues. This modality can be useful in both diagnosis and intraoperative visualisation, to help defining tumour margins and allow a more precise removal of all the cancerous mass during surgery. In this context, we have developed a series of NIR fluorescent probes that target the prostate-specific membrane antigen (PSMA), an established biomarker overexpressed in prostate cancer. Four new NIR imaging agents were prepared by conjugating the well-known urea-based PSMA targeting module to the NIR fluorophore Cy7.5, with linkers of 7, 10, 17 and 24 atoms. The affinity of each probe for PSMA was assessed through competitive binding and IC measurement in prostate cancer cells, using a previously reported PSMA-targeted NIR probe (i.e. PSMA-IRDye800CW) as reference. The NIR probe PSMA-Cy7.5_2 demonstrated a high affinity for PSMA (i.e. IC = 58.8 nM) and was further studied in mouse xenograft models of prostate cancer, to assess its ability to image PSMA positive tumour tissues. While PSMA-Cy7.5_2 out-performed PSMA-IRDye800CW in vitro, its tumour accumulation in vivo was not as evident. Further micellar aggregation studies indicated that the relatively higher hydrophobic property of PSMA-Cy7.5_2 may lower its bioavailability and tissue distribution following systemic injection, limiting its ability of targeting PSMA tumour in vivo. Nevertheless, the excellent binding capability of PSMA-Cy7.5_2 renders this probe a valid lead for further structural optimisation to develop imaging analogues with high affinity and specificity for PSMA, as required for effective NIR fluorescence-guided applications pre-clinically and clinically.
肿瘤靶向近红外(NIR)光学成像是检测恶性组织的一种新兴工具。这种方式在诊断和术中可视化方面都很有用,可以帮助确定肿瘤边界,并允许在手术过程中更精确地切除所有癌变组织。在这种情况下,我们开发了一系列靶向前列腺特异性膜抗原(PSMA)的 NIR 荧光探针,PSMA 是前列腺癌中过表达的一种已确立的生物标志物。我们通过将著名的基于尿素的 PSMA 靶向模块连接到 NIR 荧光团 Cy7.5 上来制备四个新的 NIR 成像剂,连接体的原子数分别为 7、10、17 和 24。通过使用先前报道的靶向 PSMA 的 NIR 探针(即 PSMA-IRDye800CW)作为参比物,在前列腺癌细胞中通过竞争性结合和 IC 测量来评估每个探针对 PSMA 的亲和力。NIR 探针 PSMA-Cy7.5_2 对 PSMA 表现出高亲和力(即 IC = 58.8 nM),并进一步在前列腺癌的小鼠异种移植模型中进行了研究,以评估其对 PSMA 阳性肿瘤组织成像的能力。虽然 PSMA-Cy7.5_2 在体外的性能优于 PSMA-IRDye800CW,但在体内其肿瘤积累并不明显。进一步的胶束聚集研究表明,PSMA-Cy7.5_2 相对较高的疏水性可能会降低其在系统注射后的生物利用度和组织分布,从而限制其在体内靶向 PSMA 肿瘤的能力。尽管如此,PSMA-Cy7.5_2 的出色结合能力使其成为进一步结构优化的有效先导,以开发具有高亲和力和特异性的 PSMA 成像类似物,从而在临床前和临床中实现有效的 NIR 荧光引导应用。